Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its ...
Our round-up of biotech financings is led this week by Braveheart Bio, a San Francisco biotech that has launched with $185 ...
Eisai has already reached settlement agreements with two other companies seeking to market Lenvima generics in the US – Sun ...
According to the White House, Novo Nordisk's semaglutide-based Ozempic for diabetes and Wegovy for obesity will cost $350 per ...
HES can provide the kind of real-world evidence that some life sciences companies have a great deal of difficulty in ...
The second batch of Commissioner's national priority vouchers (CNPVs) has been published by the FDA, and includes new GLP-1 agonists for weight-loss from Eli Lilly and Novo Nordisk and drugs for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback